<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01025297</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-107-07</org_study_id>
    <nct_id>NCT01025297</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone</brief_title>
  <acronym>Eclipse 2</acronym>
  <official_title>A Phase I/IIa Dose Escalation Study of Repeated Administration of &quot;CYT107&quot; (Glyco-r-hIL-7) Add-On Treatment in Genotype 1 or 4 Hcv Infected Patients Resistant to Pegylated Interferon-Alpha and Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytheris SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytheris SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety of biological active dose of a new experimental&#xD;
      drug, IL-7, in combination with standard bi-therapy in patients with Hepatitis C chronic&#xD;
      infection identified as non responders to the standard bi-therapy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/IIa inter-patient dose-escalation study assessing weekly doses of&#xD;
      Interleukin-7 (CYT107) in adult patients infected by virus genotype 1 or 4 of Hepatitis C and&#xD;
      resistant to standard treatment with Peg-Interferon and Ribavirin (bitherapy).&#xD;
&#xD;
      The dose escalation is aimed at establishing the safety of a biologically active doses of&#xD;
      CYT107 added to the combination therapy of pegylated interferon-alpha and ribavirin. At each&#xD;
      dose level, study patients will receive one subcutaneous administration of CYT107 per week&#xD;
      for a total of 4.&#xD;
&#xD;
      Groups of 6 patients will be entered at each dose level of CYT107. Three dose levels are&#xD;
      planned.&#xD;
&#xD;
      Eligible patients initially receive bi-therapy for 6-10 weeks. Thereafter, CYT107 is added&#xD;
      for a cycle of four weekly injections at a defined dose level while standard bi-therapy&#xD;
      continues for 9 weeks after CYT107 treatment discontinuation. The patients are then followed&#xD;
      on a regular basis until reaching 48 weeks after the CYT107 treatment. The duration of study&#xD;
      is approximatively 60 weeks with 20-25 weeks of bi-therapy.&#xD;
&#xD;
      Participants will have 1 overnight hospitalization and 15 clinic visit on a period of 60&#xD;
      weeks.&#xD;
&#xD;
      During the visits the following may be done:&#xD;
&#xD;
        -  medical history, physical examination, blood tests&#xD;
&#xD;
        -  electrocardiograms (ECG)&#xD;
&#xD;
        -  chest X-Ray&#xD;
&#xD;
        -  liver/spleen imaging&#xD;
&#xD;
        -  urine tests&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate at W 12 the safety of biologically active doses of CYT107 added to a combination therapy by pegylated interferon-alpha and ribavirin</measure>
    <time_frame>12 weeks after the start of IL-7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize pharmacokinetics and pharmacodynamics of CYT107</measure>
    <time_frame>12 weeks after the start of IL-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in the context of a dose escalation strategy the potential anti-viral effect of CYT107</measure>
    <time_frame>12 weeks after the start of IL-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immune specific response to HCV</measure>
    <time_frame>12 weeks after the start of IL-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To document the long-term safety and viral load variations</measure>
    <time_frame>48 weeks after the start of IL-7</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>CYT107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-7</intervention_name>
    <description>3 dose levels: 3, 10 &amp; 20 µg/kg. 4 administrations, 1 per week</description>
    <arm_group_label>CYT107</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genotype 1 or 4 infected patients&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Absence of viral response to previous treatments with pegylated interferon-alpha plus&#xD;
             ribavirin defined as:&#xD;
&#xD;
               -  Absence of early viral response (EVR) with detectable HCV and with a decrease HCV&#xD;
                  RNA load &lt; 2 logs, measured by a quantitative PCR tests after 12 weeks of&#xD;
                  treatment, as compared to baseline levels measured by a similar technique; or&#xD;
&#xD;
               -  Absence of end of treatment response defined by detectable HCV RNA at the end of&#xD;
                  treatment (24 weeks or 48 weeks)&#xD;
&#xD;
          -  Metavir ≤ F3 assessed by biopsy in the last 12 months or by fibroscan if Fibroscan®&#xD;
             result &lt; 10 kPa in the last 6 months (biopsy can be avoided)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection by HBV (positive HBs Ag or positive anti HBc antibodies with a&#xD;
             detectable HBV DNA viral load).&#xD;
&#xD;
          -  Infection by HIV-1 and /or HIV-2&#xD;
&#xD;
          -  Apart from HCV infection, presence of active infection requiring a specific treatment&#xD;
             or a hospitalization&#xD;
&#xD;
          -  Other liver disease (notably from alcoholic, metabolic or immunological origin)&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 30kg/m2&#xD;
&#xD;
          -  Relapse after previous response to pegylated IFN alpha and ribavirin therapy&#xD;
&#xD;
          -  Any history of malignancy apart from curatively treated basal cell carcinoma or in&#xD;
             situ cervical carcinoma&#xD;
&#xD;
          -  History of clinical autoimmune disease or active auto-immune disease&#xD;
&#xD;
          -  History of severe asthma, presently on chronic medications&#xD;
&#xD;
          -  Significant cardiac or pulmonary disease&#xD;
&#xD;
          -  Prior solid organ or hematopoietic cell transplantation&#xD;
&#xD;
          -  Dialyzed patient&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tilman Gerlach</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital of San Gallen-Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaujon Hospital</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Kremlin Bicêtre</name>
      <address>
        <city>Kremlin Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria, Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fatebenefratelli e Oftalmico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele Scientific Institute</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interleukin-7</keyword>
  <keyword>immune-based therapies</keyword>
  <keyword>hepatitis C</keyword>
  <keyword>chronic hepatitis</keyword>
  <keyword>resistance to Peg-interferon and ribavirin bi-therapy</keyword>
  <keyword>immune specific responses to HCV</keyword>
  <keyword>phase 1/2a</keyword>
  <keyword>viral disease</keyword>
  <keyword>liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

